+++
CHAPTER SUMMARY AND CENTRAL ILLUSTRATION
++
Content Update
AEGIS-II Trial: Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction
This phase 3 randomized, placebo-controlled trial assessed the efficacy and safety of CSL112, a human plasma-derived apolipoprotein A1 that increases cholesterol efflux capacity, in high-risk patients (multivessel coronary artery disease, and pharmacologic treatment of diabetes or two additional risk factors: age 65 years or older, history of MI, peripheral artery disease) after acute myocardial infarction (MI). Read More
++
Content Update
DanGer Shock
The DanGer Shock trial was an international, multicenter, randomized, open-label trial to assess the addition of a microaxial flow pump (Impella CP, Abiomed) to usual care in patients with ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock (CS) undergoing revascularization. Key exclusion criteria included out of hospital cardiac arrest with Glasgow Coma Scale (GCS) of less than 8 on arrival. Read More
++
Content Update
EMPACT-MI Trial Review
The EMPACT-MI investigators evaluated whether the addition of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, to the standard treatment for acute myocardial infarction (AMI) affected future mortality or heart failure (HF) in at-risk patients. Read More
++
Content Update
ECLS-SHOCK Trial Review
The ECLS-SHOCK trial evaluated the impact of extracorporeal life support (ECLS) on mortality in patients with acute myocardial infarction (AMI) complicated by cardiogenic shock. Read More
++
Content Update
MULTISTARS AMI: MULTIvessel Immediate versus STAged RevaScularization in Acute Myocardial Infarction
The MULTISTARS AMI trial was a prospective, randomized, noninferiority trial designed to compare the safety and efficacy of immediate versus staged percutaneous coronary intervention (PCI) of nonculprit vessels among hemodynamically stable patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease, after successful primary PCI of the infarct-related coronary artery. Read More
++
Content Update
BIOVASC: Immediate Versus Staged Complete Revascularization in ACS and Multivessel Disease
The BIOVASC trial was a prospective, open-label, non-inferiority, randomized, multinational clinical trial designed to assess whether immediate versus staged (within 6 weeks after the index procedure) complete revascularization improves outcomes in patients with acute coronary syndromes (ACS) and multivessel coronary disease. Read More
++
Content Update
BRIGHT-4: a randomized trial of bivalirudin in patients with ST-segment elevation myocardial infarction
BRIGHT-4 was an open-label, randomized trial comparing bivalirudin utilizing a post-percutaneous coronary intervention (PCI) high-dose infusion protocol to heparin alone in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. Read More
++
Content Update
SECURE Trial
The SECURE trial is an open-label, multinational trial that randomized 2,499 patients aged ≥65 years with a prior type 1 myocardial infarction (MI) within the 6 months preceding enrollment to a polypill-based strategy with a single pill containing aspirin (100 mg), ramipril (2.5, 5 or 10 mg) and atorvastatin (20 or 40 mg), or to usual care. Read More
++
Content Update
PACMAN-AMI: Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients with Acute Myocardial Infarction
The PACMAN-AMI ...